Role of sodium glucose cotransporter-2 inhibitors in type I diabetes mellitus

References

• American Diabetes Association Standards of medical care in diabetes-2013 Diabetes Care 2013 35 S11 S63
   Web of Science ®Google Scholar
• Gorsuch A Spencer K Lister J Evidence for a long prediabetic period in type 1 (insulin-dependent) diabetes mellitus Lancet 1981 2 8260–8261 1363 1365 6118756
   PubMed Web of Science ®Google Scholar
• Knip M Siljander H Autoimmune mechanisms in type 1 diabetes Autoimmunity Rev 2008 7 7 550 557 18625444
   PubMed Web of Science ®Google Scholar
• Kilpatrick ES Rigby AS Atkin SL Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: “double diabetes” in the Diabetes Control and Complications Trial Diabetes Care 2007 30 707 771 17327345
   PubMed Web of Science ®Google Scholar
• George P McCrimmon RJ Potential role of non-insulin adjunct therapy in type 1 diabetes Diabetic Med 2013 30 179 188 22804102
   PubMed Web of Science ®Google Scholar
• Vella S Buetow L Royle P Livingstone S Colhoun HM Petrie JR The use of metformin in type 1 diabetes: a systematic review of efficacy Diabetologia 2010 53 5 809 820 20057994
   PubMed Web of Science ®Google Scholar
• Bhat R Bhansali A Bhadada S Sialy R Effect of pioglitazone therapy in lean type 1 diabetes mellitus Diabetes Res Clin Pract 2007 78 349 354 17543413
   PubMed Web of Science ®Google Scholar
• Stone M Walker J Chisholm D The addition of rosiglitazone to insulin in adolescents with type 1 diabetes and poor glycaemic control: a randomized-controlled trial Pediatr Diabetes 2008 9 4 Pt 1 326 334 18466213
   PubMed Web of Science ®Google Scholar
• Rabasa-Lhoret R Burelle Y Ducros F Use of an alpha-glucosidase inhibitor to maintain glucose homoeostasis during postprandial exercise in intensively treated type 1 diabetic subjects Diabet Med 2001 18 9 739 744 11606172
   PubMed Web of Science ®Google Scholar
• Nagai E Katsuno T Miyagawa J Effects of miglitol in combination with intensive insulin therapy on blood glucose control with special reference to incretin responses in type 1 diabetes mellitus Endocr J 2011 58 869 877 21869539
   PubMed Web of Science ®Google Scholar
• Whitehouse F Kruger D Fineman M A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care 2002 25 724 730 11919132
   PubMed Web of Science ®Google Scholar
• Ratner R Whitehouse F Fineman MS Adjunctive therapy with pramlintide lowers HbA1C without concomitant weight gain and increased risk of severe hypoglycemia in patients with type 1 diabetes approaching glycemic targets Exp Clin Endocrinol Diabetes 2005 113 199 204 15891954
   PubMed Web of Science ®Google Scholar
• Garg SK Moser EG Bode BW Effect of sitagliptin on postprandial glucagon and GLP-1 levels in patients with type 1 diabetes: Investigator-initiated, double-blind, randomized, placebo-controlled trial Endocr Pract 2013 19 19 28 23186950
   PubMed Web of Science ®Google Scholar
• Kielgast U Krarup T Holst JJ Madsbad S Four weeks of treatment with liraglutide reduces insulin dose without loss of glycemic control in type 1 diabetic patients with and without residual beta-cell function Diabetes Care 2011 34 1463 1468 21593296
   PubMed Web of Science ®Google Scholar
• Polsky S Ellis SL Obesity, insulin resistance, and type 1 diabetes mellitus Curr Opin Endocrinol Diabetes Obes 2015 22 4 277 282 26087341
   PubMedGoogle Scholar
• Vick H Diedrich DF Baumann K Reevaluation of renal tubular glucose transport inhibition by phlorizin analogs Am J Physiol 1973 224 3 552 557 4691268
   PubMed Web of Science ®Google Scholar
• Vallon V Thomson SC Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney Annu Rev Physiol 2012 74 351 375 22335797
   PubMed Web of Science ®Google Scholar
• Washburn WN Poucher SM Differentiating sodium-glucose co-transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus Expert Opin Investig Drugs 2013 22 463 486
   PubMed Web of Science ®Google Scholar
• FORXIGA™ (dapagliflozin) now approved in European Union for treatment of type 2 diabetes 11 2012 Available from: https://www.astrazeneca.com/media-centre/press-releases/2012/FORXIGA-dapagliflozin-now-approved-in-European-Union-for-treatment-of-type-2-diabetes-14112012 Accessed November 14, 2012
   Google Scholar
• FDA approves Invokana to treat type 2 diabetes 3 2013 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm Accessed November 14, 2012
   Google Scholar
• FDA approves Jardiance (empagliflozin) to treat type 2 diabetes 8 2014 Available from: https://www.drugs.com/newdrugs/fda-approves-jardiance-empagliflozin-type-2-diabetes-4064.html Accessed November 14, 2012
   Google Scholar
• Ferrannini E Ramos SJ Salsali A Tang W List JF Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial Diabetes Care 2010 33 10 2217 2224 20566676
   PubMed Web of Science ®Google Scholar
• Bailey CJ Iqbal N T’Joen C List JF Dapagliflozin monotherapy in drug-naive patients with diabetes: a randomized-controlled trial of low-dose range Diabetes Obes Metab 2012 14 10 951 959 22776824
   PubMed Web of Science ®Google Scholar
• Kaku K Kiyosue A Inoue S Efficacy and safety of dapagliflozin monotherapy in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise Diabetes Obes Metab 2014 16 11 1102 1110 24909293
   PubMed Web of Science ®Google Scholar
• Bailey CJ Gross JL Pieters A Bastien A List JF Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo controlled trial Lancet 2010 375 9733 2223 2233 20609968
   PubMed Web of Science ®Google Scholar
• Henry RR Murray AV Marmolejo MH Hennicken D Ptaszynska A List JF Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial Int J Clin Pract 2012 66 5 446 456 22413962
   PubMed Web of Science ®Google Scholar
• Rosenstock J Seman LJ Jelaska A Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia Diabetes Obes Metab 2013 15 12 1154 1160 23906374
   PubMed Web of Science ®Google Scholar
• Haring HU Merker L Seewaldt-Becker E Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 2014 37 6 1650 1659 24722494
   PubMed Web of Science ®Google Scholar
• Strojek K Yoon KH Hruba V Elze M Langkilde AM Parikh S Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial Diabetes Obes Metab 2011 13 10 928 938 21672123
   PubMed Web of Science ®Google Scholar
• Haring HU Merker L Seewaldt-Becker E Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial Diabetes Care 2014 37 1480 1483 24595630
   PubMed Web of Science ®Google Scholar
• Wilding J Charpentier G Hollander P Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial Int J Clin Pract 2013 67 12 1267 1282 24118688
   PubMed Web of Science ®Google Scholar
• Forst T Guthrie R Goldenberg R Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone Diabetes Obes Metab 2014 16 5 467 477 24528605
   PubMed Web of Science ®Google Scholar
• Rosenstock J Vico M Wei L Salsali A List JF Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy Diabetes Care 2012 35 7 1473 1478 22446170
   PubMed Web of Science ®Google Scholar
• Kovacs C Seshiah V Swallow R Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial Diabetes Obes Metab 2014 16 2 147 158 23906415
   PubMed Web of Science ®Google Scholar
• Jabbour SA Hardy E Sugg J Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study Diabetes Care 2014 37 3 740 750 24144654
   PubMed Web of Science ®Google Scholar
• Roden M Weng J Eilbracht J Empagliflozin monotherapy in drug-naıve patients with type 2 diabetes: a randomised, 24-week, double-blind, placebo-controlled, parallel group, trial with sitagliptin as active comparator Lancet Diabetes Endocrinol 2013 1 3 208 219 24622369
   PubMed Web of Science ®Google Scholar
• Rosenstock J Jelaska A Frappin G Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes Diabetes Care 2014 37 7 1815 1823 24929430
   PubMed Web of Science ®Google Scholar
• Liakos A Karagiannis T Athanasiadou E Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis Diabetes Obes Metab 2014 16 10 984 993 24766495
   PubMed Web of Science ®Google Scholar
• Yang X Lai D Zhong X Shen HP Huang YL Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis Eur J Clin Pharmacol 2014 70 10 1149 1158 25124541
   PubMed Web of Science ®Google Scholar
• Scheen A Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus Drugs 2015 75 33 59 25488697
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ de Zeeuw D Wie L Leslie B List J Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes Diabetes Obes Metab 2013 15 9 853 862 23668478
   PubMed Web of Science ®Google Scholar
• Majewski C Bakris G Blood pressure reduction: an added benefit of sodium–glucose cotransporter 2 inhibitors in patients with type 2 diabetes Diabetes Care 2015 48 429 430
   Web of Science ®Google Scholar
• Reddy R Inzucchi S SGLT2 inhibitors in the management of type 2 diabetes Endocrine 2016 53 2 364 372 27270407
   PubMed Web of Science ®Google Scholar
• Luippold G Klein T Mark M Grempler R Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus Diabetes Obes Metab 2012 14 601 22268612
   PubMed Web of Science ®Google Scholar
• Cheng S Chen L Li S Mayoux E Leung PS The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes PLoS One 2016 11 1 e0147391 26807719
   PubMed Web of Science ®Google Scholar
• Perkins B Cherney D Partridge H Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial Diabetes Care 2014 37 1480 1483 24595630
   PubMed Web of Science ®Google Scholar
• Mudaliar S Armstrong D Mavian A Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes Diabetes Care 2012 35 2198 2200 23011728
   PubMed Web of Science ®Google Scholar
• Henry R Rosenstock J Edelman S Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study Diabetes Care 2015 38 3 412 419 25271207
   PubMed Web of Science ®Google Scholar
• Henry R Thakkar P Tong C Polidori D Alba M Efficacy and safety of canagliflozin, a sodium glucose cotransporter 2 inhibitor, as add-on to insulin in patients with type 1 diabetes Diabetes Care 2015 38 12 2258 2265 26486192
   PubMed Web of Science ®Google Scholar
• Sands A Zambrowicz B Rosenstock J Sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, as adjunct therapy to insulin in type 1 diabetes Diabetes Care 2015 38 7 1181 11188 26049551
   PubMed Web of Science ®Google Scholar
• Cherney DZ Perkins BA Soleymanlou N Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus Circulation 2014 129 5 587 597 24334175
   PubMed Web of Science ®Google Scholar
• Cnop M Welsh N Jonas J-C Jörns A Lenzen S Eizirik DL Mechanisms of pancreatic-cell death in type 1 and type 2 diabetes many differences, few similarities Diabetes 2005 54 2 S97 S107 16306347
   PubMed Web of Science ®Google Scholar
• Vetere A Choudhary A Burns SM Wagner BK Targeting the pancreatic β-cell to treat diabetes Nat Rev Drug Discov 2014 13 278 289 24525781
   PubMed Web of Science ®Google Scholar
• Jurczak MJ Lee HY Birkenfeld AL SGLT2 deletion improves glucose homeostasis and preserves pancreatic B-cell function Diabetes 2011 60 3 890 898 21357472
   PubMed Web of Science ®Google Scholar
• Cheng ST Chen L Li SYT Mayoux E Leung PS The effects of empagliflozin, an SGLT2 inhibitor, on pancreatic β-cell mass and glucose homeostasis in type 1 diabetes PLoS One 2016 11 1 e0147391 26807719
   PubMed Web of Science ®Google Scholar
• Stenlöf K Cefalu WT Kim KA Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Diabetes Obes Metab 2013 15 4 372 382 23279307
   PubMed Web of Science ®Google Scholar
• Kalra S Sahay R Gupta Y Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis Indian J Endocrinol Metab 2015 19 4 524 26180770
   PubMedGoogle Scholar
• Kalra S Gupta Y Patil S Sodium-glucose cotransporter-2 inhibition and the insulin: glucagon ratio: unexplored dimensions Indian J Endocrinol Metab 2015 19 426 429 25932403
   PubMedGoogle Scholar
• U.S. Food and Drug Administration Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood [Internet] 15 5 2015 Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/UCM446954.pdf Accessed June 22, 2015
   Google Scholar
• European Medicines Agency Review of diabetes medicines called SGLT2 inhibitors started: risk of diabetic ketoacidosis to be examined [Internet] 12 6 2015 Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/SGLT2_inhibitors__20/Procedure_started/WC500187926.pdf Accessed June 22, 2015
   Google Scholar
• Abdul-Ghani M Del Prato S Chilton R DeFronzo RA SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study Diabetes Care 2016 39 5 717 725 27208375
   PubMed Web of Science ®Google Scholar
• Mudaliar S Alloju S Henry RR Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis Diabetes Care 2016 39 7 1115 1122 27289124
   PubMed Web of Science ®Google Scholar
• Tomaselli GF Zipes DP What causes sudden death in heart failure? Circ Res 2004 95 754 763 15486322
   PubMed Web of Science ®Google Scholar
• Cahill GFJr Veech RL Ketoacids? Good medicine? Trans Am Clin Climatol Assoc 2003 114 149 161 12813917
   PubMedGoogle Scholar